Dovitinib (TKI258)

DRUG4 trials

Sponsors

Novartis Pharmaceuticals, University of Virginia

Conditions

Adenoid Cystic CarcinomaAdvanced Solid Tumors, Excluding Breast CancerGastrointestinal Stromal TumorsTumor Pathway Activations Inhibited by Dovitinib

Phase 1

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.

CompletedNCT01700270

Novartis PharmaceuticalsAdvanced Solid Tumors, Excluding Breast Cancer

Start: 2013-05-31End: 2014-08-31Updated: 2020-12-21

Phase 2

Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib

CompletedNCT01478373

Novartis PharmaceuticalsGastrointestinal Stromal Tumors

Start: 2012-01-31End: 2014-07-31Updated: 2016-04-27

Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma

CompletedNCT01524692

University of VirginiaAdenoid Cystic Carcinoma

Start: 2012-03-31End: 2015-12-31Updated: 2018-11-09

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

CompletedNCT01831726

Novartis PharmaceuticalsTumor Pathway Activations Inhibited by Dovitinib

Start: 2013-08-31End: 2015-12-31Updated: 2017-03-20

Related Papers

A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma (ACC).

Journal of Clinical Oncology2015-05-204 citations

Anti-tumor effects of dovitinib in patient-derived gastrointestinal stromal tumor (GIST) xenograft models.

Journal of Clinical Oncology2015-05-20

The signature program, a series of tissue-agnostic, mutation-specific signal finding trials.

Journal of Clinical Oncology2014-05-202 citations